AU642876B2 - Dihydrospirorenone as an antiandrogen - Google Patents

Dihydrospirorenone as an antiandrogen

Info

Publication number
AU642876B2
AU642876B2 AU55094/90A AU5509490A AU642876B2 AU 642876 B2 AU642876 B2 AU 642876B2 AU 55094/90 A AU55094/90 A AU 55094/90A AU 5509490 A AU5509490 A AU 5509490A AU 642876 B2 AU642876 B2 AU 642876B2
Authority
AU
Australia
Prior art keywords
dihydrospirorenone
antiandrogen
treatment
premenopause
oestrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU55094/90A
Other languages
English (en)
Other versions
AU5509490A (en
Inventor
Sybille Dr. Beier
Walter Dr. Elger
Yukishige Dr. Nishino
Rudolf Dr. Wiechert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6380839&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU642876(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering AG filed Critical Schering AG
Publication of AU5509490A publication Critical patent/AU5509490A/en
Application granted granted Critical
Publication of AU642876B2 publication Critical patent/AU642876B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Dental Preparations (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AU55094/90A 1989-05-16 1990-05-16 Dihydrospirorenone as an antiandrogen Expired AU642876B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3916112 1989-05-16
DE3916112A DE3916112A1 (de) 1989-05-16 1989-05-16 Dihydrospirorenon als antiandrogen

Publications (2)

Publication Number Publication Date
AU5509490A AU5509490A (en) 1990-11-22
AU642876B2 true AU642876B2 (en) 1993-11-04

Family

ID=6380839

Family Applications (1)

Application Number Title Priority Date Filing Date
AU55094/90A Expired AU642876B2 (en) 1989-05-16 1990-05-16 Dihydrospirorenone as an antiandrogen

Country Status (20)

Country Link
US (1) US5569652A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0398460B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP2848919B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1033948C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE154881T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU642876B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR1101055A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2016780C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DD (1) DD294417A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (3) DE3916112A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK0398460T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2106728T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (1) GR3024861T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HU213408B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IE (1) IE81143B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL94416A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LU (1) LU91065I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL300221I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT94038B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA903754B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4321957C2 (de) * 1993-07-01 1995-09-28 Marika Dr Med Ehrlich Verwendung eines hormonalen Mittels zur Therapie der Akne
DE4344462C2 (de) 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
DE19651000A1 (de) * 1996-12-01 1998-06-04 Schering Ag Oxyiminopregnancarbolactone
US6787531B1 (en) 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
EP2305267A3 (en) 1999-08-31 2011-08-17 Bayer Schering Pharma Aktiengesellschaft Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive
NZ517845A (en) 1999-08-31 2004-12-24 Schering Ag Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive
US20020132801A1 (en) * 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
JP5350572B2 (ja) * 2000-12-20 2013-11-27 バイエル ファーマ アクチエンゲゼルシャフト シクロデキストリン−ドロスピレノン封入複合体
EP1216713A1 (en) 2000-12-20 2002-06-26 Schering Aktiengesellschaft Compositions of estrogen-cyclodextrin complexes
EP1216712A1 (en) 2000-12-20 2002-06-26 Schering Aktiengesellschaft Cyclodextrin-drospirenone inclusion complexes
JP2005522466A (ja) * 2002-03-18 2005-07-28 ファルマシア・コーポレーション アルドステロン受容体アンタゴニスト、およびニコチン酸またはニコチン酸誘導体の組合わせ
BR0308517A (pt) * 2002-03-18 2005-02-01 Pharmacia Corp Combinação de um antagonista do receptor de aldosterona e de um agente sequestrante de ácido biliar
WO2004070048A1 (en) * 2003-02-07 2004-08-19 Pharmacia & Upjohn Company Llc A microbial process to prepare 5-androsten-3beta, 7alpha, 15alpha-triol-17-one and related analogues
ATE429900T1 (de) * 2004-03-10 2009-05-15 Bayer Schering Pharma Ag Zusammensetzungen aus drospirenon in molekularer dispersion
MY142989A (en) * 2004-03-10 2011-02-14 Bayer Schering Pharma Ag Stabilised supersaturated solids of lipophilic drugs
US20050220825A1 (en) * 2004-03-10 2005-10-06 Adrian Funke Molecular dispersions of drospirenone
DE102004026679A1 (de) 2004-05-28 2005-12-15 Grünenthal GmbH Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat
DE102004026669A1 (de) * 2004-05-28 2005-12-15 Grünenthal GmbH Verwendung einer Kombination aus Ethinylestradiol und Chlormadinonacetat zur Herstellung eines Arzneimittels
DE102004026671A1 (de) * 2004-05-28 2005-12-15 Grünenthal GmbH Darreichungsform zur hormonalen Kontrazeption
DE102004026670A1 (de) 2004-05-28 2005-12-15 Grünenthal GmbH Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat
ITMI20042338A1 (it) * 2004-12-06 2005-03-06 Ind Chimica Srl Processo per la preparazione di drospirenone
US8475838B2 (en) * 2005-06-03 2013-07-02 Sandoz Ag Rapidly-dissolving pharmaceutical composition for inhibiting ovulation
ES2311927T5 (es) * 2005-07-21 2014-09-08 Bayer Pharma Aktiengesellschaft Proceso para la producción de 3-oxo-pregn-4-en-21,17-carbolactonas por la oxidación sin metales de 17-(3-hidroxipropil)-3,17-dihidroxiandrostanos
US7319154B2 (en) 2005-07-21 2008-01-15 Bayer Schering Pharma Ag Process for the production of 3-oxo-pregn-4-ene-21, 17-carbolactones by the metal free oxidation of 17-(3-hydroxypropyl)-3, 17-dihydroxyandrostanes
US20070275941A1 (en) * 2006-05-17 2007-11-29 Vladimir Hanes Salt sensitivity and prevention of hypertension with drospirenone
CN102083418A (zh) * 2008-04-24 2011-06-01 伊万斯彻有限公司 口服避孕药剂及其制备方法
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP3936133A1 (en) 2011-11-23 2022-01-12 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
EP3145489A1 (en) 2014-05-22 2017-03-29 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2652761C2 (de) * 1976-11-16 1985-11-21 Schering AG, 1000 Berlin und 4709 Bergkamen 15,16-Methylen-Spirolactone, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
DE3022337A1 (de) * 1980-06-11 1982-01-07 Schering Ag Berlin Und Bergkamen, 1000 Berlin Praeparate zur kontrazeption und zur behandlung gynaekologischer stoerungen
US4347245A (en) * 1981-05-26 1982-08-31 German Shapiro Spironolactone-containing composition and use thereof
JPS59139400A (ja) * 1983-01-31 1984-08-10 Shionogi & Co Ltd 抗アルドステロン活性ステロイド誘導体
DE3402329A1 (de) * 1984-01-20 1985-08-01 Schering AG, 1000 Berlin und 4709 Bergkamen 6,6-ethylen-15,16-methylen-3-oxo-17(alpha)-pregn-4-en-21,17-carbolactone, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
US4855289A (en) * 1984-06-04 1989-08-08 Wester Per O Combination of two active substances
US4729999A (en) * 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency
DE3615376A1 (de) * 1986-05-07 1987-11-12 Schering Ag 2,2;6,6-diethylen-3-oxo-17(alpha)-pregn-4-en-21,17-carbolactone, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
DK174724B1 (da) * 1986-07-15 2003-10-06 Wyeth Corp Anvendelse af et præparat omfattende et østrogen og et progestogen til fremstilling af en dosisform til tilvejebringelse af hormonerstatningsterapi og kontraception til kvinder i præmenopausen samt pakning til tilvejebringelse af præparatet

Also Published As

Publication number Publication date
JPH0395121A (ja) 1991-04-19
NL300221I1 (nl) 2006-04-03
DE59010730D1 (de) 1997-08-07
IL94416A (en) 1997-07-13
EP0398460A3 (de) 1991-09-25
DE122004000006I1 (de) 2006-06-08
PT94038B (pt) 1997-06-30
NL300221I2 (nl) 2006-11-01
ATE154881T1 (de) 1997-07-15
CA2016780C (en) 2000-07-11
DD294417A5 (de) 1991-10-02
LU91065I2 (fr) 2004-03-30
HU903045D0 (en) 1990-09-28
US5569652A (en) 1996-10-29
IE81143B1 (en) 2000-04-19
JP2848919B2 (ja) 1999-01-20
CA2016780A1 (en) 1990-11-16
ZA903754B (en) 1991-02-27
PT94038A (pt) 1991-01-08
DE3916112C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1992-04-30
EP0398460A2 (de) 1990-11-22
ES2106728T3 (es) 1997-11-16
IL94416A0 (en) 1991-03-10
AU5509490A (en) 1990-11-22
GR3024861T3 (en) 1998-01-30
BR1101055A (pt) 2000-08-08
HU213408B (en) 1997-06-30
DE3916112A1 (de) 1990-11-22
DK0398460T3 (da) 1998-02-16
HUT54500A (en) 1991-03-28
IE901738L (en) 1990-11-16
CN1047299A (zh) 1990-11-28
EP0398460B1 (de) 1997-07-02
CN1033948C (zh) 1997-02-05

Similar Documents

Publication Publication Date Title
AU642876B2 (en) Dihydrospirorenone as an antiandrogen
CA2299366A1 (en) Use of xanthophylls for improvement of duration of muscle function or treatment of muscle disorders or diseases
HUT75103A (en) Once-day metoprolol oral dosage form and process for it's preparation
PL299814A1 (en) Pharmaceutical preparation inhibiting depletion of human bone tissue
CA2096350A1 (en) Treatment for osteoporosis using growth hormone release factor (grf) in combination with parathyroid hormone (pth)
ZA895090B (en) Novel benzopyran derivatives,processes for their preparation and their use and preparations containing the compounds
DE69710896D1 (en) Progestogen-anti-progestogen therapien
NZ332105A (en) Medicaments including human growth hormone for the treatment of type II diabetes and metabolic syndrome
IL120558A0 (en) New hormonal medicaments and their use for the correction of oestrogenic deficiencies
AU8602391A (en) Therapeutic device for correcting misalignment of center of gravity of human body
CA2280685A1 (en) A medicament against infertility and for increasing fertility
AU5702890A (en) Therapeutic agents of metabolic bone disease
CA2101548A1 (en) Acylamino-alkylidenhydroxy-bisphosphonic acids useful in the therapy of osteoarticular diseases
HUT73500A (en) Use of benzydamine for producing pharmaceutical compositions for treatment of pathological conditions caused by tnf
EP0408525A3 (en) Use in therapy of 10-amino-5,6-dihydro-11h-dibenzo(b,e)azepine-6,11-dione and derivatives as drugs for use in the treatment of urinary incontinence
AU1494395A (en) The use of deoxyspergualin for preparing a pharmaceutical for treating hyperreactive inflammatory diseases
ZA919261B (en) An imidazobenzodiazepine for the treatment of sleep disorders
AU5003490A (en) Chin support for use during anaesthesia
GB8600666D0 (en) Apparatus for surgical & medical uses
AU4252889A (en) Apparatus for positioning the head of a patient, notably during an ophthalmological examination or treatment
UA10248A (uk) Спосіб лікування ішемічної хвороби серця на фоні цукрового діабету
GB8805732D0 (en) Surgical/medical dressing for tube fixation